

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hilong Holding Limited

海隆控股有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1623)

**ANNOUNCEMENT PURSUANT TO
RULES 13.51B(2) AND 13.51(2)(H) OF THE LISTING RULES**

This announcement is made by Hilong Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(h) of The Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the regulatory announcement dated 4 December 2023 published by the Stock Exchange (the “**Regulatory Announcement**”) in relation to the disciplinary action taken by the Stock Exchange against Hong Kong Resources Holdings Company Limited (stock code: 2882) (“**Hong Kong Resources Holdings**”) and its directors (including, among others, Dr. Fan Ren Da Anthony (“**Dr. Fan**”), a non-executive director of the Company). Dr. Fan currently serves as an independent non-executive director, a member of the audit committee, a member of the nomination committee and a member of the remuneration committee of Hong Kong Resources Holdings.

According to the Regulatory Announcement, Dr. Fan was publicly censured by the Listing Committee of the Stock Exchange (the “**Listing Committee**”) for breaching Rule 3.08 of the Listing Rules and his declaration and undertaking given to the Stock Exchange in the form set out in Appendix 5B to the Listing Rules by failing to comply with the Listing Rules to the best of his ability and to use his best endeavour to procure the compliance by Hong Kong Resources Holdings in respect of the money lending business. Dr. Fan has been directed by the Listing Committee to attend 20 hours of training on regulatory and legal topics including Listing Rules compliance (the “**Training Requirements**”). For further details, please refer to the Regulatory Announcement on the Stock Exchange’s website.

For the avoidance of doubt, the Regulatory Announcement relates to Hong Kong Resources Holdings only and (other than Dr. Fan mentioned above) does not involve any director or senior management of the Company.

The board of directors (the “**Board**”) of the Company has reviewed the Regulatory Announcement (and the statement of disciplinary action referred therein). In view of (i) the findings and conclusions contained in the Regulatory Announcement do not indicate that Dr. Fan is unsuitable to act as a director of a company listed on the Stock Exchange; (ii) the event set out in the Regulatory Announcement does not involve any act of dishonesty or fraud concerning, or doubt cast on the integrity of, Dr. Fan; and (iii) Dr. Fan has confirmed to the Company that he will strictly comply with the Training Requirements, and taking into account of the background, expertise and contributions of Dr. Fan, the Board does not believe that Dr. Fan’s ability to act as a non-executive director of the Company will be adversely affected.

Save as disclosed in this announcement, Dr. Fan has confirmed to the Company that there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

For and on behalf of the Board
Hilong Holding Limited
ZHANG Jun
Chairman

Hong Kong, 5 December 2023

As at the date of this announcement, the executive directors of the Company are Mr. ZHANG Jun and Mr. WANG Tao (汪濤); the non-executive directors are Ms. ZHANG Shuman, Dr. YANG Qingli, Mr. CAO Hongbo and Dr. Fan Ren Da Anthony; and the independent non-executive directors are Mr. WANG Tao (王濤), Mr. WONG Man Chung Francis and Mr. SHI Zheyang.

* *For identification purpose only*